Cargando…
First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
INTRODUCTION: Metastatic colorectal cancer (mCRC) is one of the most common cancers and the second leading cause of cancer worldwide. With the improvement of systemic and operative therapies, median overall survival (mOS) reached 30 months or longer. Here, we will review the use of the anti-vascular...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
De Gruyter
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604573/ https://www.ncbi.nlm.nih.gov/pubmed/31579770 http://dx.doi.org/10.1515/iss-2018-0012 |